Health Deserves A Vision More Capacious Than Dashboard Metrics
Consumer health and wellness is experiencing a flurry of activity. The lab testing company Function (motto: “It’s time to own your health”) acquired Ezra, a... Read More
Biotech Leaders Get It
About David Shaywitz
David Shaywitz, MD PhD is a contributing writer for Timmerman Report.
Focus: the transformational opportunities and implementation challenges presented by emerging technologies in healthcare, biomedical discovery, and biopharmaceutical development, from NGS and cell therapies to digital biomarkers and the meaningful application of AI. Co-author (with Lisa Suennen): Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology? (Hyperink Press, 2014).
Background: Drawing on two decades of biopharma experience, Dr. Shaywitz applies deep R&D expertise to guide and invest in the strategic adoption of emerging technologies to accelerate the discovery, development and delivery of impactful new therapies for patients.
Dr. Shaywitz’s career has centered on advancing pharmaceutical research by appreciating the transformative potential of nascent technologies while also recognizing the unique challenges of incorporating these technologies into complex biopharma environments. He has particular expertise in guiding promising technology and technology innovators through the complex scientific, cultural, and organizational landscape of biopharma.In addition to his writing for TR, Dr. Shaywitz is also a frequent speaker and writer on topics at the intersection of medicine, science, and innovation, and contributes book reviews regularly to the Wall Street Journal.
Dr. Shaywitz serves as a lecturer in the Department of Biomedical Informatics at Harvard Medical School, is an advisor to the MS/MBA Biotechnology Life Science Program at Harvard GSAS/HBS, and is an Adjunct Scholar at the American Enterprise Institute.
Latest Contributions
Tech-Enabled Power To The People: Ingratiating Chatbots and a Virtuous Food App
For at least a decade, nearly every tech company has promoted their product as facilitating the “democratization” of something – perhaps “data driven medicine,” or... Read More
Our Collective Hope For AI in Health, Plus Explanatory Models and an Epic Podcast
A recent piece by Nathan Price captures our collective hope for AI in health with unusual clarity, even as there remains impassioned disagreement regarding how... Read More
Can You Improve Your Health Without Obsessing About It?
Can you improve your health without obsessing about it? I’ve been, well, obsessing about this question as I continue to spend more time and mindshare... Read More
GLP-1s Secret Weapon: Improving Health By Enhancing Agency
The arrival of generative AI prompted many to worry about the adverse impact on human agency; after all, if the technology can effectively do what... Read More
Longevity Is Having A Moment
Dying, with few exceptions, has never been especially popular, and our shared interest in not dying hardly constitutes breaking news. Nevertheless, the aspiration of living... Read More
Sluggish Corporate AI Adoption Has Motivated Entrepreneurs To Pick Their Spots
As economic historian Carlota Perez has described, there is typically a significant time lag between when the promise of novel technology begins to emerge and... Read More
Rewiring, Not Retiring: Health and Innovation for the Vanguard Generation
Most of my columns tend to focus on the importance and difficulty of applying emerging technologies to biopharma R&D, aiming to accelerate the delivery of... Read More